1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Covalon Technologies Ltd.

Covalon Technologies Ltd.

COV.V
Covalon Technologies Ltd.CA flagToronto Stock Exchange Ventures
2.20
CAD
+0.05
- -
60.76MMarket Cap
Covalon Technologies Ltd.
COV.V
(Toronto Stock Exchange Ventures)

Recent

price

2.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.43
0.31
0.46
0.45
0.97
0.82
0.56
1.36
1.24
1.51
0.52
0.76
0.7
1.07
1.28
1.2
1.19
Revenue per Share
-0.53
-0.43
-0.48
-0.11
0.26
-0.1
-0.26
0.09
0.08
-0.41
-0.27
0.91
-0.38
-0.18
0.11
0.08
0.06
Basic EPS, GAAP
-0.02
-0.43
-0.42
-0.18
0.32
-0.27
-0.11
-0.02
-0.06
-0.18
-0.24
0.02
-0.35
-0.18
0.13
0.05
0.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.15
Dividend per Share
-3.33
-3.42
-0.06
-0.11
0.15
0.05
-0.03
0.23
0.35
0.17
-0.12
0.79
0.39
0.18
0.66
0.66
0.56
Book Value per Share
0.67
0.54
0.14
0.1
0.39
0.32
0.18
0.37
0.55
-0.02
-0.23
1.26
0.89
0.69
1.07
1.07
0.97
Tangible Book Value per Share
7
8
8
9
9
9
12
20
22
22
26
26
26
25
24
27
28
Basic Weighted Avg Shares
3
3
4
4
9
8
7
27
27
34
14
20
18
27
31
33
33
Sales/Revenue/Turnover
-63.26
-139.67
-102.41
-24.37
26.96
-9.99
-47.03
6.63
6.05
-24.26
-54.69
4.29
-50.38
-17.03
6.9
5.37
3.49
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
Depreciation Expense
-4
-4
-4
-1
2
-1
-3
2
2
-9
-7
23
-10
-4
3
2
2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-121.78
-137.63
-105.22
-24.02
26.51
-12.41
-47.03
6.63
6.05
-26.87
-51.47
120.02
-53.25
-16.77
8.57
6.27
5.02
Profit Margin (%)
5
4
1
1
4
3
2
7
11
4
-8
32
23
16
25
28
24
Working Capital
- -
- -
- -
1
1
- -
- -
- -
- -
6
3
2
2
1
- -
2
1
LT Debt
8
7
3
3
6
5
4
9
13
15
9
33
24
19
28
31
28
Total Equity
- -
- -
- -
- -
52.72
- -
- -
32.67
15.27
- -
- -
2.54
- -
- -
8.82
5.75
3.7
Return on Invested Capital (%)
- -
- -
- -
- -
315.56
- -
- -
85.83
23.47
- -
- -
117.09
- -
- -
23.3
11.01
9.2
Return on Capital (%)
- -
- -
- -
- -
- -
-101.19
- -
- -
26.39
-159.36
- -
- -
-63.63
-62.21
26.1
12.02
9.86
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
27
28
28
Market Capitalization
58
48
50

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'26
Mar'26
Total Current Assets
32
28
28
Cash, Cash Equivalents & STI
17
18
17
Accounts Receivable, Net
6
2
5
Inventories
7
7
6
Total Current Liabilities
4
5
4
Payables & Accruals
3
4
3
ST Debt
1
1
- -
Deferred Revenue
- -
1
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.1%
54.94%
11.72%
Free Cash Flow
-209.89%
-504.73%
-52.81%
Net Income, GAAP
-144.49%
-163.09%
-22.91%
Sales/Revenue/Turnover
37.32%
21.33%
5.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
8
9
9
31
2025
8
8
8
9
33
2026
7
9
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
0.06
0.06
0.02
0.11
2025
0.04
0.02
- -
- -
0.08
2026
- -
0.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
0.15
- -
- -
- -
- -
Similar Companies
tella, Inc. (2191.T)
Capricor Therapeutics, Inc. (CAPR)
Gc Cell Corp. (144510.KQ)
Savara Inc. (SVRA)
Panion & Bf Biotech Inc. (1760.TW)
Satsuma Pharmaceuticals, Inc. (STSA)
Business
Covalon Technologies Ltd. is a research-driven developer, manufacturer and marketer of patent-protected medical products focused on advanced wound care, infection management, vascular access, perioperative care and customized medical device coatings. The company offers a comprehensive portfolio of solutions including collagen matrix dressings such as ColActive Plus and ColActive Plus Ag for chronic and infected wounds like diabetic foot ulcers, pressure ulcers and surgical wounds; vascular access products including VALGuard line guards, IV Clear dual-antimicrobial clear IV dressings and CovaClear IV soft silicone dressings for sensitive skin; perioperative care items; urology products; and proprietary coating technologies like CovaCoat utilizing photo-polymerization processes. Founded in 2004 and headquartered in Mississauga, Ontario, Canada, Covalon sells its branded products directly and through private label arrangements and license contracts to pediatric and acute care hospitals, long-term care settings and home healthcare providers throughout the United States, Canada, Latin America and the Middle East. In a significant recent development, the company engaged Origin Merchant Partners in May 2025 as its financial and strategic advisor to explore opportunities including joint ventures, mergers, licensing deals, a potential NASDAQ listing, stock repurchases from its approximately $18 million net cash reserves and separations of its Advanced Wound Care and Vascular Access Surgical Consumables divisions to maximize shareholder value; additionally, Covalon announced its first-ever dividend payment in November 2025, marking a milestone in financial strength amid revenue growth to $24.1 million in the first nine months of fiscal 2025.